

Innate immune response in CF airway epithelia: hyperinflammatory?

Terry E. Machen

Department of Molecular and Cell Biology, University of California, Berkeley, California

Machen, Terry E. Innate immune response in CF airway epithelia: hyperinflammatory? *Am J Physiol Cell Physiol* 291: C218–C230, 2006; doi:10.1152/ajpcell.00605.2005.—The lack of functional cystic fibrosis (CF) transmembrane conductance regulator (CFTR) in the apical membranes of CF airway epithelial cells abolishes cAMP-stimulated anion transport, and bacteria, eventually including *Pseudomonas aeruginosa*, bind to and accumulate in the mucus. Flagellin released from *P. aeruginosa* triggers airway epithelial Toll-like receptor 5 and subsequent NF- κ B signaling and production and release of proinflammatory cytokines that recruit neutrophils to the infected region. This response has been termed hyperinflammatory because so many neutrophils accumulate; a response that damages CF lung tissue. We first review the contradictory data both for and against the idea that epithelial cells exhibit larger-than-normal proinflammatory signaling in CF compared with non-CF cells and then review proposals that might explain how reduced CFTR function could activate such proinflammatory signaling. It is concluded that apparent exaggerated innate immune response of CF airway epithelial cells may have resulted not from direct effects of CFTR on cellular signaling or inflammatory mediator production but from indirect effects resulting from the absence of CFTRs apical membrane channel function. Thus, loss of Cl^- , HCO_3^- , and glutathione secretion may lead to reduced volume and increased acidification and oxidation of the airway surface liquid. These changes concentrate proinflammatory mediators, reduce mucociliary clearance of bacteria and subsequently activate cellular signaling. Loss of apical CFTR will also hyperpolarize basolateral membrane potentials, potentially leading to increases in cytosolic $[\text{Ca}^{2+}]$, intracellular Ca^{2+} , and NF- κ B signaling. This hyperinflammatory effect of CF on intracellular Ca^{2+} and NF- κ B signaling would be most prominently expressed during exposure to both *P. aeruginosa* and also endocrine, paracrine, or nervous agonists that activate Ca^{2+} signaling in the airway epithelia.

Pseudomonas aeruginosa; Toll-like receptor; NF- κ B; oxidative stress; acidic airway surface liquid; calcium

ARE INNATE HOST RESPONSES IN CF “HYPERINFLAMMATORY”?

UNDER NORMAL CONDITIONS, the airways remain relatively sterile due to the efficient action of the mucociliary escalator. The lack of functional cystic fibrosis (CF) transmembrane conductance regulator (CFTR) in the apical membranes of CF airway epithelial cells abolishes cAMP-stimulated anion transport, and bacteria, eventually including *Pseudomonas aeruginosa*, accumulate in the mucus (180) and trigger a dramatic inflammatory response to the infection. The innate immune response of the epithelial cells to these bacteria in the airway surface liquid (ASL) involves the activation of receptors and signaling pathways, production, and release of proinflammatory cytokines and the recruitment of macrophages and neutrophils to the infected region. The most important *P. aeruginosa* product triggering the early inflammatory responses is flagellin, the monomer that comprises the structural shaft of the flagellum (134). These flagellin subunits activate Toll-like

receptor (TLR)-5 (58) in the apical membranes of airway epithelial cells (179, 199). Signaling through MyD88-IRAK-TRAF and p38 MAP kinases (199), and perhaps Ca^{2+} (1, 137), activates NF- κ B and AP-1 transcription factors that regulate proinflammatory genes. Although TLRs 2, 6, 9, and 10 and perhaps others are also expressed (5, 52, 61, 199), they appear to be much less important in early responses to the luminal bacteria (59, 179, 199). In particular, LPS and other released bacterial products (10, 52, 112) appear only to activate weak inflammatory responses in airway epithelia (179), and then only at very high concentrations (59, 71). It should be noted that although the earliest inflammatory signaling in response to *P. aeruginosa* seems to be controlled by flagellin-TLR5-NF- κ B, other bacterial products and epithelial signaling pathways may be important during infections with other common CF pathogens, including *Staphylococcus aureus* (50, 137), *Haemophilus influenzae* (19, 138), or *Burkholderia cepacia* (181). This may also pertain to the situation occurring during persistent, extended infections with *P. aeruginosa*, because under these conditions the bacteria become immotile, presumably resulting from the loss of flagella (see 152). In this circumstance, inflammation may be maintained by *P. aeruginosa* secreting quorum-sensing homoserine lactones (162),

Address for reprint requests and other correspondence: T. E. Machen, Dept. of Molecular and Cell Biology, 231 LSA, Univ. of California at Berkeley, Berkeley, CA 94720-3200 (e-mail: tmachen@berkeley.edu).

alginate (30), pyocyanin (34, 136), and/or other secreted factors like proteases and exotoxin A: any or all of these may trigger proinflammatory signaling in airway epithelial cells. *P. aeruginosa* also secrete other virulence factors that may contribute to the proinflammatory state (see Ref. 152 for review).

Although the inflammatory responses to the bacteria occur on a grand scale in CF airways, there is great uncertainty whether the CF airway epithelia exhibit such a large inflammatory response because so many bacteria have accumulated, or, alternatively, because the epithelia have an inherent defect leading to a hyperinflammatory state, in which there is constitutive production and secretion of inflammatory cytokines and increased responses to the presence of bacteria.

Some studies have found increased numbers of inflammatory cells and IL-8 in bronchoalveolar lavage (BAL) from CF patients with either mild disease symptoms or in the absence of demonstrable microorganisms (16, 17, 80, 111, 115, 150, 176). There is also *in vivo* evidence of reduced production of anti-inflammatory products like IL-10 (16, 17) and lipoxins (76). Many studies have found that CF airway epithelial cells in culture have constitutively active NF- κ B and upregulated expression and secretion of IL-8 and other inflammatory mediators (12, 23, 33a, 35, 36, 41, 54, 90, 167, 171, 174, 183, 186, 190). In some cases, these phenotypes were largely reversed in CFTR-corrected cells or in cells incubated at 25°C, which increased mutant CFTR movement from the ER to the plasma membrane (e.g., 41, 159). This apparent inherent hyperinflammatory state may be further stimulated by the presence of *P. aeruginosa* (39, 176), though not always (23).

Microarray methods have recently been used to test for differences in gene expression in CF vs. non-CF or CFTR-corrected cells. Some experiments have shown that *patterns* of gene expression (i.e., specific genes) were different in CF vs. CFTR-corrected cell (41, 141, 167). Whitsett and colleagues (197, 198) have described similar differences in expression of specific genes in the lungs of wild-type, CF knockout, and Δ F508CFTR mice at different stages of development. The most prominent effects of the lack of wild-type CFTR expression were on genes related to redox balance and regulation [particularly in genes related to glutathione (GSH) homeostasis], heat shock or stress, ion transport, and CFTR-interacting proteins (198). Although there were increases in expression of some pro-inflammatory genes (e.g., IL-1 β , TNF- α -induced protein 3, colony stimulating factor-3 receptor), most of these changes were relatively small (<2-fold) and there were no increases in the well-known proinflammatory mediators like IL-8 and TNF- α (197). Overall, these microarray studies of the lungs of mice were consistent with the studies of cells in culture in showing that the absence of CFTR had selective effects to regulate specific genes, but, unlike the *in vitro* studies, the *in vivo* results indicated that genes involved in regulating inflammatory processes were not prominently affected.

In contrast, Perez and Davis (124) found similar gene expression patterns but different *magnitudes* of responses to *P. aeruginosa* strain PAO1 in CF vs. non-CF cells. Kelley and colleagues (78, 79, 88, 168) found that CF cells have inefficient Jak-stat1 signaling, reducing nitric oxide synthase 2 expression. Exuberant NF- κ B signaling (174) or reduced nitric oxide

production leading to destabilized I κ B and increased NF- κ B activity (84) in CF have been proposed to explain these hyperinflammatory phenotypes.

In contrast to these studies showing apparent intrinsic hyperinflammation in CF cells, Dakin et al. (32) showed that early infection in CF was the likely explanation for the enhanced inflammatory responses in CF lungs. This result was consistent with other *in vivo* measurements of inflammatory mediators in BAL fluids showing that increased inflammation in CF followed bacterial infections (5). Recent studies using terminal restriction fragment length polymorphism profiling of sputum from both adult (149) and pediatric (148) CF patients have shown many (>40) bacterial species that have not been previously identified in CF. Most of these bacteria were metabolically active, indicating that they could potentially play a role in pathogenesis. It therefore seems possible that previous *in vivo* studies that observed inflammation in the apparent absence of infection may have suffered from undetected bacteria.

Technical differences may also explain the apparent hyperinflammatory phenotype observed *in vitro*. Thus a comprehensive study by Aldallal et al. (3) compared the cell lines used by many research groups, and also used adenovirus to express CFTR in CF cells to ensure isogenic comparisons between the CF and the CFTR-corrected cells, including primary airway epithelial cells. They showed that different responses of normal, CF and CFTR-corrected airway epithelia were likely due to differences in cells, and were unrelated to the presence of CFTR. Pizurki et al. (130) used the adenoviral method to express CFTR in a CF cell line and similarly showed that inflammatory responses to cytokines were similar in CF and CFTR-corrected cells. Also, Becker et al. (10) showed that normal and CF primary airway epithelial cells exposed to bacterial supernatants caused equivalent activation of cytokine expression and secretion, though they did observe differences between CF and non-CF after 24 h of treatment. Joseph et al. (74) have also shown that long-term incubation with *P. aeruginosa* caused larger innate immune responses in CF cells compared with non-CF, consistent with previous work (90) showing that long-term bacterial exposure may magnify differences in inflammatory responses between CF and non-CF or CFTR-corrected epithelia.

Although a firm conclusion is presently impossible, we propose that subtle technical artifacts have contributed to the apparent proinflammatory phenotype observed by many investigators in studies of CF vs. non-CF or CFTR-corrected airway epithelia. *In vivo* experiments demonstrating inflammatory mediators in CF BAL fluids in the absence of bacterial infections may have suffered from undetected bacteria or bacterial products. Although it is clear that the CF cell line (IB3) exhibits a pro-inflammatory status compared with matched cells with integrated wild-type CFTR (C38) (e.g., 36, 41, 166, 167), there are no differences in constitutive or stimulated inflammatory responses among IB3 cells, IB3 cells that had been CFTR-corrected using an adenovirus and cells infected with adenovirus expressing a control transgene (3), indicating that there were non-CFTR-dependent differences between the IB3 and C38 cell lines. Similar problems may explain proinflammatory differences observed between other similar

pairings, including 9/HTEO-pCEP-R ("CF") – 9/HTEO/pCEP (non-CF) cells (e.g., 52).

In this regard, Babnigg et al. (6) have observed variability in store-operated Ca^{2+} influx into human embryonic kidney-293 cells, and they argue, based on a careful analysis of this variability, that isolating clones from a heterogeneous population can lead to clones with significantly different Ca^{2+} influx, even though they were isolated from the same parent population. They further argue that it is important to compare effects of gene expression based on transfections of many cells (>200). Growing only a few transfected cells can yield a biased population. This problem might contribute to the apparent differences in inflammatory properties of the IB3 vs. C38 cells or the pCEP vs. pCEPR cells. Further use of the adenoviral or similar method to make isogenic comparisons between CFTR and ΔF508 -CFTR-expressing cells would help settle such controversies because the method leads to expression of the CFTR in a high percentage of the cells and also permits comparison with vector controls.

In vitro studies of CF vs. normal primary cells may also suffer from subtle technical problems that contribute to apparent hyperinflammation in CF. Ribeiro et al. (144) have shown that ΔF508 CF primary bronchial epithelia exhibited a hyperinflammatory phenotype as defined by an increased basal and bradykinin-induced IL-8 secretion during the first 6–11 days of culture. However, this CF phenotype appeared to result from the chronic exposure in vivo to inflammatory conditions because this phenotype was lost in long-term (30 to 40 days old) cultures, and exposure of 30- to 40-day-old cultures of normal airway epithelia to supernatant from mucopurulent material from CF airways induced the hyperinflammatory phenotype in the normal cultures. These results showed that the hyperinflammatory phenotype, which also included dramatic changes in structure of the ER (144–146), was independent of mutant CFTR expression and that this phenotype was maintained for extended times in culture. Future studies of hyperinflammation in CF vs. normal primary cells will need to account for these prolonged effects of the in vivo inflammatory state on cells in culture.

The absence of a proinflammatory phenotype in CF airway epithelia would be consistent with the fact that CF epithelia like sweat duct (139) and intestine (117) that normally express CFTR at high levels do not apparently exhibit a proinflammatory phenotype. For example, CF mouse small intestine exhibits increased expression of several inflammatory markers (e.g., serum amyloid A and complement factors) and large influx of mast cells and neutrophils (117) compared with non-CF mice. These data were consistent with data obtained from CF humans showing increased levels of inflammatory markers (e.g., IL-1 β and IL-8) and nitric oxide, as well increased infiltration of monocytes (21, 133, 164). However, this inflammatory response in the intestine seems to have resulted solely from an overgrowth of luminal bacteria (116). Thus, when CF mice were treated with antibiotics, inflammatory markers and cells were reduced to those of the non-CF murine intestines (116). Interestingly, the exaggerated inflammation in CF mouse intestine was also reduced by treatment of patients with *Lactobacillus*, indicating that the specific bacterial flora were important determinants of the inflammation (116).

DOES ALTERED GOLGI pH IN CF CAUSE DEFECTS IN MEMBRANE AND MUCUS BIOCHEMISTRY AND BACTERIAL BINDING IN CF?

An early proposal (9), subsequently modified (131), was that absence of CFTR altered Golgi pH, which in turn reduced activity of Golgi enzymes leading to increased fucosylation and decreased sialylation of membrane surfaces (155, 175), including increased expression of asialoGM1 (9). *P. aeruginosa* produce lectins that bind to fucose moieties (65), and increased asialoGM1 expression and increased *P. aeruginosa* binding (12, 19, 53, 122) could increase inflammatory signaling. It has also been proposed that flagellin may activate airway epithelial cells by binding to asialoGM1 serving as co-receptor to TLR2 (1). In addition, some studies have shown altered cell surface glycosylation (135) and altered binding of some lectins in CF cells (38) or CFTR-expressing cells transfected with plasmids expressing either CFTR regulatory (R) domain or full-length ΔF508 CFTR (96). A related concept is that mucins secreted by CF airway epithelial cells could have similarly altered glycosylation and/or sulfation (e.g., 92, 143, 175) leading to bacterial binding.

However, several observations indicate that this altered Golgi pH-altered surface glycosylation hypothesis is likely to be incorrect. Seksek et al. (160) and Chandy et al. (26) showed that there were no CFTR-associated differences in Golgi pH (also see Ref. 49). Dunn et al. (39) similarly showed that pH of the endosomal compartment was not altered in CF. Instead, pH's of the Golgi and other organelles of the secretory (and perhaps endocytic) pathways appear to be regulated primarily by H^+ pumping into the organelle lumen by the well known H^+ v-ATPase balanced by a H^+ leak (26, 156, 195). The CFTR likely plays no role in controlling pH of the Golgi because the Golgi has its own K^+ and/or Cl^- conductances that dissipate the voltage associated with operation of the electrogenic H^+ v-ATPase (see Ref. 104). In this circumstance, Golgi pH will be determined by the activities and numbers of the H^+ v-ATPase and the H^+ leak and also by the cytosolic pH. Although CFTR conducts HCO_3^- and its activity affects cytosolic pH under some circumstances (132), there is no evidence that steady-state cell pH is affected by CFTR in airway epithelia.

In addition, CFTR expression in IB3 cells using an adenovirus had no effect on lectin binding (72), showing that previously measured differences were due to differences between the cell lines that were not related to CFTR expression. Furthermore, if Golgi pH and glycosylation and sulfation enzyme activities were altered in CF, it would be expected that mucins would exhibit altered glycosylation and sulfation. However, several mucins showed identical glycosylation and sulfation in CF and non-CF or CFTR-corrected cells (20, 96, 140, 150, 161).

DOES LOSS OF CFTR REDUCE BACTERIAL UPTAKE AND DISPOSAL IN CF?

Pier and colleagues have proposed that *P. aeruginosa* binds to CFTR at the first extracellular loop through interaction with the outer core oligosaccharide portion of bacterial LPS, and this binding leads to bacterial entry into the epithelial cell. Recent experiments (51, 86) have shown that CFTR may be located in lipid rafts. It is further proposed that bacterial uptake

into the cells has two beneficial effects: activation of apoptosis and cell sloughing aids in clearing bacteria from the airways, and activation of NF- κ B contributes to a subclinical, protective innate immune response and inflammation that resolves the infection (126–128). The absence of CFTR in the plasma membrane therefore reduces bacterial clearance and contributes to an overexuberant proinflammatory response (127).

Several observations indicate that this altered bacterial uptake hypothesis is likely to be incorrect. First, the hypothesis has been based partly on electron or light microscopic observations of in vivo lung specimens, and it is difficult to determine whether apparent bacterial uptake into epithelial cells was responsible for triggering apoptosis and desquamation or, alternatively, that the desquamating cells were particularly susceptible to bacterial binding and uptake, as has been observed in studies of bacterial binding on cultured airway epithelia (94). Second, the hypothesis conflicts with a number of observations. First, under normal conditions, bacterial binding to the apical surface, where CFTR is located, is infrequent (1 bacterium per 100 epithelial cells: see Refs. 128 and 129), and *P. aeruginosa* binding (94, 135) and uptake (46) occurs most prominently at the basolateral membrane of epithelia. Second, *P. aeruginosa* uptake may be negatively, not positively, correlated with CFTR expression (33). Finally, apical application of flagellin alone, even in the absence of bacteria, activates NF- κ B in all columnar cells lining the airway surface (179), showing that bacterial uptake is not required to induce a cellular innate immune response. Thus, although *P. aeruginosa* appear to be internalized by a small percentage of airway epithelial cells and internalized bacterial products could activate NF- κ B in these cells (178), it appears unlikely that CFTR plays a role in these processes.

DOES REMOVAL OF CFTR FROM SIGNALING COMPLEX TRIGGER INFLAMMATORY SIGNALING IN CF?

From measurements of regulated on activation of normal T-expressed and presumably secreted production in both CF and CFTR-corrected primary cells and cell lines IB3 cells transfected with a variety of different CFTR mutants, Schwiebert and colleagues (43, 159) concluded that CFTR expression in the plasma membrane served to inhibit AP-1 and NF- κ B signaling through interactions with EBP50 (also termed Na⁺/H⁺ exchange regulatory factor), the cytoskeleton and associated inflammatory activator proteins. In the absence of CFTR in the apical plasma membrane, this inhibition would be lifted, contributing to increased inflammatory signaling in CF. Others have similarly proposed that absence of CFTR may alter interactions with AMP kinase (AMPK) or annexin 1, either of which could play roles in controlling inflammation. AMPK is located in a similar cellular location as CFTR (54) and appears to interact with regulate its channel activity (55–57), indicating that a CFTR-AMPK “signaling complex” might exist. In addition, CF airway epithelial cell lines and primary cells expressed less AMPK and larger secretion of IL- and IL-8 than non-CF cells, and the apparent proinflammatory phenotype was reduced by treating CF cells with a chemical activator of AMPK (54). The colon, pancreatic ducts, and lung airways also express annexin 1 in similar location as

CFTR, and annexin 1 expression was reduced in CF (12). Because annexin 1 regulates phospholipase A2 and may serve an anti-inflammatory function in cells, it was argued that hyperinflammatory responses of CF airways resulted from the loss of annexin 1 (12).

Although the COOH-terminus of CFTR associates with EBP50 and other PDZ-related proteins (e.g., 53, 97, 170, 189) and could therefore serve as an organizer of a macromolecular signaling complex in or near the apical membrane of airway epithelia, it seems likely that there will be many more EBP50, AMPK, and annexin 1 molecules than CFTRs in airway epithelial cells, so the absence of CFTR may not alter the distribution and organizational function of the potential signaling partners. The modulation of AMPK through CF-induced changes in cellular [Ca²⁺] (or other signaling events) was also proposed as a connection between CFTR and AMPK (54). The potential role of CFTR in affecting or controlling cellular [Ca²⁺] will be discussed below. Alteration of annexin 1 function by cellular [Cl⁻] has been proposed to explain the different annexin function in CF vs. non-CF cells (12), although experiments on cultured nasal cells indicate that there is no difference in cell [Cl⁻] between CF and non-CF (193). Overall, it seems likely that if there is a role for CFTR in controlling proinflammatory signaling, this will be mediated not through direct molecular interactions with a signaling complex but through some indirect effect of CFTR on the cellular environment.

DOES HYPOXIA IN CF TRIGGER ROS PRODUCTION AND HYPERINFLAMMATION?

The potential roles of hypoxia and ROS-regulated signaling in controlling inflammatory processes in CF have not been considered previously, but CF could alter oxidative status of both cells and ASL through changes in oxygen use by the airway epithelial cells (Fig. 1). Using O₂-sensitive microelectrodes, Wortlisch et al. (194) found Po₂ >150 mmHg in the fluids 700–800 μ m above the surface of cultured airway epithelia. Po₂ decreased in a curvilinear manner to values <50 mmHg as the electrodes reached the surface of non-CF cells, and this hypoxia was even more pronounced in CF, with Po₂ reaching 5–15 mmHg. It was hypothesized that the lower Po₂ values in CF were due to increased Na⁺ absorption that occurs in CF cultures, leading to increased ATP consumption by the Na⁺-K⁺-ATPases in the basolateral membranes of the cells, resulting in increased O₂ consumption (18, 123, 169). On the basis of data in other cell types, hypoxia could activate MAPK and/or NF- κ B-signaling pathways leading to intrinsic inflammation even in the absence of bacteria. Thus the hypoxia-inducing factors-1 or HIF-2 of many cells are tightly controlled by cellular oxygen tension (157, 188) through reactions controlled by enzymes whose activities are dependent on [O₂] (60, 93). When [O₂] <5% (i.e., when Po₂ = 38 mmHg, close to values observed in the fluids above airway epithelial cells, Ref. 194), production of ROS by mitochondria increased (24, 25), leading to activation of signaling pathways, including p38 MAPK (25), which has been implicated (e.g., 83 and 196) as an integral downstream component of the MyD88-dependent branch of the TLR pathway as well as other pathways likely involved in the response to pathogens.




Fig. 1. Increased Na⁺ transport in cystic fibrosis (CF) causes hypoxia and production of reactive oxygen species (ROS)? It has been proposed (see Ref. 158) that the absence of CFTR increases Na⁺ absorption (shown by larger arrow) through epithelial Na⁺ channels (ENaC) (electroneutrality provided by paracellular flux of Cl⁻), leading to increased ATP utilization by basolateral Na⁺-K⁺-ATPase. The increased energy demand increases consumption of O₂ [thereby depleting P_{O2} in the airway surface liquid (ASL)] and increased production of ROS by mitochondria (shown as green in normal and red in CF). ROS could activate NF-κB signaling and contribute to inflammation.

DOES HYPERINFLAMMATION RESULT INDIRECTLY FROM CFTR'S ROLE IN CONTROLLING VOLUME, PH, AND GSH OF ASL?

CFTR is expressed in both the glands (42) and the surface epithelium (87) of the airways, and it is likely that both glands and surface cells participate in controlling the ionic composition and volume of the ASL. The glands (8, 67), primarily the acinar cells (73), appear to serve an important secretory function, with CFTR conducting both Cl⁻ and HCO₃⁻ from the cells into the lumen (64, 67, 89, 187, 191). In contrast, the surface cells appear to be capable of both secretion and absorption (182), with absorption dominating in the quiescent state in the absence of activation of cAMP/PKA signaling. Secretion by both glands and surface cells is reduced in CF (73).

Although the effects of the absence of CFTR on the composition and volume of the ASL in CF are still being debated (see Refs. 29, 70, 165), it seems likely that the absence of CFTR decreases volume of the ASL (73). This reduction in volume of the ASL would be expected to increase the concentration of other secreted products that may be proinflammatory, even in the absence of bacterial infections. For example, bradykinin and the purinergic agonists ATP, ADP, and adenosine activate inflammatory signaling (99, 106–108, 121, 144, 145), and these would all be expected to be present in increased concentrations if the volume of the ASL is reduced in CF. In addition, airway epithelial cells secrete small, but significant amounts of proinflammatory cytokines into the ASL (179), and the cells have apical receptors for these cytokines (179) that could then activate or synergize with inflammatory signaling triggered by bacteria. The magnitude of this proinflammatory, concentrating effect of reducing ASL volume will depend on the amounts of these inflammatory mediators that are secreted into the lumen and the concentration dependence of the effects of these agonists on epithelial inflammatory signaling, which remain to be tested.

CFTR may be involved in maintaining redox status of the ASL and mutations in CFTR could impair lung antioxidant defenses, thereby increasing oxidative stress in the ASL in CF airways (14, 47, 62, 151). WT-CFTR conducts reduced GSH (see Ref. 101), a key redox buffer in cells. Cells containing defective CFTR secrete less GSH than control cells containing functional CFTR, and transfection with functional CFTR restores GSH secretion (47). Furthermore, bronchioalveolar lavage fluids from CFTR-knockout mice had decreased concentrations of GSH and increased concentrations of thiobarbituric acid-reactive substances and 8-hydroxy-2-deoxyguanosine, two indicators of oxidative stress. However, tissue concentrations of GSH were similar, and the activities of GSH reductase and GSH peroxidase were increased, whereas the activity of γ-glutamyltransferase was unchanged (185), indicating that changes in redox may not always occur in CF. It remains to be determined whether increased ASL oxidation in CF results directly from the absence of CFTR or indirectly from the infiltration of leucocytes that produce ROS and also whether increased ASL oxidation affects cytosolic redox. However, no matter how the oxidative stress in CF originates, such oxidation could potentially activate NF-κB (75) and p38 MAP kinase (81, 98, 105) and hyperinflammatory responses (185) (Fig. 2).

The acidity of ASL appears to increase in CF, and this could similarly affect cellular signaling. The ASL of both normal and CF airways is slightly more acidic than plasma (29, 69, 70, 91), and nongastric H⁺-K⁺-ATPase (29), v-type H⁺-ATPase (67), and Zn²⁺-sensitive H⁺ conductance (45) in the apical membranes of the epithelial cells may all contribute to this acidity.




Fig. 2. ASL redox and/or pH controls inflammatory signaling in CF? According to this model, normal airway epithelial cells (left) conduct reduced glutathione (GSH) and HCO₃⁻ from the cell cytosol to the ASL through CF transmembrane conductance regulator (CFTR), and these transport activities are reduced in CF (right). GSH is in equilibrium with oxidized GSH (GSSG), and HCO₃⁻ and H⁺ are in equilibrium according to the well known reaction shown. Relative concentrations of GSH, GSSG, HCO₃⁻, and H⁺ in normal and CF are shown by the type sizes. CFTR thereby helps maintain a less oxidized and less acidic ASL than in CF. Reduced GSH and HCO₃⁻ transport in CF leads to increased oxidation and acidity of the ASL, which then act on the cytosol to activate NF-κB and contributes to inflammatory signaling in CF.

CFTR conducts HCO_3^- (64, 132), and both submucosal glands (8, 67, 165, 177; also see Refs. 89 and 95) and surface epithelium (29, 120) secrete HCO_3^- into the ASL. The absence of CFTR is expected to reduce HCO_3^- secretion and because H^+ secretion is likely to be unaffected in CF (29), this will increase ASL acidity in CF (29, but also see Ref. 69). Because extracellular pH can influence intracellular pH, increased ASL acidity in CF could alter cell signaling leading to inflammation (Fig. 2). Such an effect of luminal pH on epithelial signaling has been observed in the CF mouse intestine (77): the duodenum is abnormally more acidic in CF than in non-CF due to decreased HCO_3^- secretion through CFTR, and this increased acidity in the intestinal lumen triggers the intestine to signal the exocrine pancreas (likely through secretin) to increase HCO_3^- secretion. Normalizing duodenal pH of CF mice corrected these effects.

Even in the absence of effects of reduced volume and increased oxidation and/or acidification ASL on inflammatory signaling, the altered ASL is expected to have secondary, proinflammatory effects, e.g., reduced clearance and increased accumulation of bacteria. For example, altered ASL may lead to increased mucin cross-linking and viscosity and reduced ciliary beating and mucociliary clearance (125). However, it should be noted that mucociliary clearance in vivo is reduced by <50% in CF (Ref. 11; see also Refs. 100 and 109), whereas there is a much larger percentage increase in accumulation in bacteria and subsequent activation of inflammation in CF. A possible explanation for these apparently contradictory data is that small reductions in mucociliary transport may accumulate over time, leading to the bacterial accumulation characteristic of the disease (see also Refs. 31 and 82).

INCREASED INTRACELLULAR Ca_i AND INFLAMMATORY SIGNALING RESULTING FROM ER “STRESS” IN CF?

The role of Ca_i^{2+} in inflammatory processes has been controversial. Some studies showed that both intact *P. aeruginosa* (107, 137) and flagellin (1, 108) increased cytosolic $[\text{Ca}_i^{2+}]$, intracellular Ca_i^{2+} (Ca_i), and activation of NF- κ B or other inflammatory signaling (1, 106–108, 137). In addition, increased NF- κ B signaling was reproduced by thapsigargin, the Ca_i^{2+} -ATPase/SERCA pump blocker, which increases Ca_i in cells, and blocked by the cellular Ca_i^{2+} -buffer BAPTA-AM (137). Ca_i -elevating agonists like bradykinin and ATP also increase cytokine expression and secretion (145, 147). However, there is also evidence that elevations of Ca_i are not involved in activating innate immune responses triggered by *P. aeruginosa*. Strains PAO1 and PAK activate NF- κ B and IL-8 expression and secretion in JME/CF15 and Calu-3 cells without affecting Ca_i (63, 68, 103). Flagellin also activates NF- κ B and IL8 secretion in Calu-3 and JME/CF15 cells without affecting Ca_i (Z. Fu and T. Machen, unpublished observations), and TLR signaling is not known to trigger increases in Ca_i in other cell types (2). The discrepancies among studies which found *P. aeruginosa*- or flagellin-induced increases in Ca_i and those which did not may result from subtle differences in bacterial preparations or epithelial cells, or in amounts of ATP released into the extracellular fluid (which would trigger Ca_i^{2+} signaling; see Refs. 106–108) during addition of the bacteria to the epithelial cells. Overall, it appears that elevating Ca_i by

treatment with purinergic agonists, bradykinin or thapsigargin is sufficient to increase activation of NF- κ B, but elevations in Ca_i are not required to activate inflammatory signaling in response to *P. aeruginosa* or flagellin in airway epithelia. Ca_i may play an important role, though, because during *P. aeruginosa* treatment, purinergic agonists elicit synergistic activation of NF- κ B mediated through increases in Ca_i (82).

A model linking mutation in CFTR to altered Ca_i signaling and inflammation is that ER stress resulting from accumulation of excessive amounts of misfolded ΔF508 CFTR in the ER lumen increases Ca_i , perhaps due to increased Ca_i^{2+} leakage from the ER (190) (Fig. 3). The increased Ca_i might then activate NF- κ B (3), contributing to inflammation. ΔF508 CFTR (~70% of patients) is a processing mutant that exhibits abnormal folding in the ER, leading to its retention (27, 191) and subsequent removal and degradation by proteosomes (48). The ER also stores Ca_i^{2+} , and altered Ca_i^{2+} handling by the ER has been observed in cells treated with adenoviruses that lead to ER accumulation of misfolded proteins (118, 119; also see Ref. 122). ER stress can also activate NF- κ B (122), and it has been proposed that ER accumulation of ΔF508 CFTR leads to activation of NF- κ B in the absence of bacterial stimulus (190; also see Ref. 7).

There are, however, inconsistencies with the ER stress: hyperinflammation hypothesis. First, CFTR is expressed at relatively low copy numbers (<5,000 channels in the apical plasma membrane of epithelial cells, e.g., see Ref. 110), and, though ΔF508 CFTR is ~100% degraded in the ER, WT-CFTR is 75% degraded (only 25% reaches the plasma membrane) (27, 85), and it seems unlikely that a 25% difference in ER retention of this low abundance protein could trigger a stress response. A similar argument is relevant for ΔF508 CFTR/WTCFTR heterozygotes, which exhibit normal Ca_i signaling but likely experience ER retention of ΔF508 CFTR that is not much different from CF individuals. Second, measurements of Ca_i that supported the ER stress- Ca_i hypothesis (190) were based on small (20%) differences in fluo-3 fluorescence, which is difficult to quantitate because it is a nonratiometric dye. Measurements of Ca_i using the ratiometric dye fura-2 could help settle this issue (see Ref. 113). Because recent experiments on Calu-3 cells indicate that CFTR processing in cells that express “normal,” as opposed to overexpressed, levels of CFTR may be different (184), it would be useful to compare a variety of CF vs. non-CF vs. CFTR-corrected cells.

INCREASED Ca_i RESULTING FROM HYPERPOLARIZED MEMBRANE POTENTIALS IN CF?

Another model that could connect CFTR to Ca_i signaling and inflammation is through effects of CFTR on cell membrane potentials, which will alter the electrical driving force for Ca_i^{2+} entry into the cells from the ASL or serosal fluid (Fig. 4). An early study (142) showed that Ca_i responses to histamine and prostaglandin E1, but not to carbachol, were reduced in CF cell lines compared with non-CF cells. In addition, adding the purinergic agonists ATP or UTP to the apical surface of primary airway epithelia elicited larger responses in CF than in non-CF, though Ca_i responses to basolateral ATP or UTP were similar in CF and non-CF cells (121). The different responses

ER Stress-Ca²⁺ Model




Fig. 3. Endoplasmic reticulum (ER) stress in CF increases cytosolic [Ca²⁺]. Retention and degradation of ΔF508CFTR in the ER and associated proteasomes (not shown) in CF might alter intracellular Ca²⁺ (Ca_i) through effects on ER Ca²⁺ accumulation by ATPase (SERCA) or leak (inositol triphosphate receptor, IP₃R). Increased Ca_i might then activate NF-κB and contribute to inflammation in CF.

to apical vs. basolateral agonists appears (144–146) to result from the fact that unidentified factors that accumulate in the mucopurulent material of the CF ASL cause dramatic structural and functional changes of the airway epithelia. The ER adjacent to the apical membranes expanded, leading to increased capability for Ca²⁺ storage and release, whereas ER adjacent to the basolateral membrane was unaffected in CF (144–146). The apical- and basolateral-localized ER operated independently from each other due to the presence of surrounding mitochondria that prevented apical or basolateral Ca_i changes from being propagated to the rest of the cell (146). Thus responses to apical agonists were larger than responses to basolateral agonists. These mucopurulent material-induced changes in cell structure and Ca_i signaling were accompanied

Cell Voltage-Ca²⁺ Entry Model




Fig. 4. Cell voltage hyperpolarization in CF increase cytosolic [Ca²⁺]. Loss of CFTR leads to a hyperpolarization of the basolateral membrane potential of airway epithelial cells from about -45 to -60 mV, and this hyperpolarization is expected to increase Ca²⁺ entry into the cells through voltage-independent calcium release-activated Ca²⁺ channels (CRAC) (green), resulting in increased Ca_i and activation of NF-κB. According to this model, differences in Ca²⁺ entry and Ca_i (and therefore in NF-κB activation) between normal and CF would be most apparent manifest during conditions in which CFTR and CRAC channels were both active. In this condition, CFTR would have its most profound effect on membrane voltage, and Ca²⁺ entry pathways will be operating.

by increases in production and release of IL-8, consistent with a potential role for Ca_i in a hyperinflammatory response.

In addition to identifying a potential role for factors in the CF ASL controlling epithelial cell structure and function, these results raise the issue of the potential interactive roles of CFTR and Ca_i in controlling or synergizing innate immune responses of airway epithelia. Ca²⁺ entry into airway epithelia will likely be required to sustain elevated Ca_i over extended periods, and a potential link among CFTR, Ca_i, and inflammation is through CFTR's effects on membrane potentials (Fig. 4). A relationship among Ca²⁺ entry, membrane voltage and inflammation was discovered first in lymphocytes by Cahalan and colleagues (40, 114), who found that membrane voltage was regulating Ca²⁺ entry into the cells through voltage-insensitive Ca²⁺ channels (28) (store-operated or transient receptor potential, TRP) by changes in electrical driving force on Ca²⁺. The resulting oscillations in Ca_i controlled inflammatory signaling and gene expression. Although there have been no studies of the effects of membrane potential on gene expression in airway epithelia, previous studies (44) in CFTR-expressing T84 intestinal epithelial cells showed that changes in membrane potential caused expected changes in Ca_i during agonist-induced activation of Ca²⁺ entry pathways. It therefore seems possible that differences in apical and/or basolateral membrane potentials (V_{ap} and/or V_{bl}) in CF vs. non-CF airway epithelia could lead to differences in apical vs. basolateral Ca²⁺ entry and Ca_i signaling and, consequently, increased activation of NF-κB (see Ref. 37) and innate host responses in CF vs. non-CF airway epithelia. These proposed effects of membrane potential on Ca²⁺ entry into CF and non-CF airway epithelial cells remain to be tested.

V_{ap} and V_{bl} are determined by the dominant ion conductances (i.e., to Na⁺, K⁺, and Cl⁻), the respective ion concentration gradients across the membranes, and the transepithelial resistance. Microelectrode measurements of V_{ap} and V_{bl} in intact epithelial sheets of CF and non-CF human airway and sweat duct epithelia, both of which express apical CFTR and ENaC, have been summarized in Table 1. Data for other

Table 1. V_{ap} and V_{bl} in non-CF and CF epithelia

	V _{ap} , mV	V _{bl} , mV	Reference No.
Nasal (human)			192, 193
Non-CF	-23	-38	
CF	-16	-52	
Sweat duct (human)			139
Non-CF	-25	-35	
CF	+26	-50	
Tracheal (bovine)			182
Activated CFTR (+fsk)	-12	-57	
Inactive CFTR (-fsk)	+2	-72	
Airway Calu-3 Line (human)			173
Activated CFTR (+fsk)	-22	-44	
Inactive CFTR (-fsk)	-48	-60	
Mammary Line (mouse)			15
Activated CFTR (+fsk)	-47	-57	
Block CFTR (+fsk+NPPB)	-61	-67	

CF, cystic fibrosis; CFTR, CF transmembrane conductance regulator; V_{ap}, apical membrane potential; V_{bl}, basolateral membrane potential. The table summarized membrane potentials measured across the apical or basolateral membranes of CFTR-expressing epithelia. V_{ap} is referenced cell vs. apical solution and V_{bl} is referenced cell vs. basolateral solution. Data for human nasal epithelia were average values taken from Refs. 192 and 193.

epithelia, in which there were comparisons of cells where CFTR was either inactive or active have also been included (Table 1). When CFTR is inactive (i.e., in unstimulated non-CF epithelia or in CF epithelia), V_{ap} and V_{bl} are largely determined by the activity of apical ENaC, which depolarizes both membranes, and basolateral K^+ conductances, which hyperpolarize both membranes. Expression and activation of CFTR in the apical membrane is expected to move V_{ap} toward the Cl^- equilibrium potential, which is approximately -22 mV (assuming an intracellular Cl^- activity of 43 mM, see Ref. 173). The data in Table 1 show that activated CFTR hyperpolarizes V_{ap} in nasal epithelia, sweat duct, and bovine trachea, tissues that have depolarized V_{ap} (likely owing to ENaC activity) in the basal state. In Calu-3 and mouse mammary epithelium, which express little apical ENaC and have hyperpolarized V_{ap} in the basal state, activation of CFTR depolarized both V_{ap} and V_{bl} (Table 1). Thus reduction of apical Cl^- permeability through the loss of functional CFTR in CF either hyperpolarizes or depolarizes V_{ap} but consistently hyperpolarizes V_{bl} (Table 1). It is therefore predicted that Ca^{2+} entry across the basolateral membrane will increase in CF (see Refs. 44 and 154), especially during treatments with agonists that activate Ca^{2+} entry channels in the basolateral membrane. Although the CF-dependent changes in V_{bl} appear small (Table 1), they could be important if, as preliminary data suggest (103), Ca_i plays an important synergistic role in flagellin-TLR-NF- κ B signaling. Synergistic interactions among NF- κ B and Ca_i -signaling pathways could become especially important during extended infections because inflammatory signaling may alter expression of gene products, which will affect Ca_i signaling, giving rise to a positive feedback situation of inflammation enhancing inflammation.

In summary, although there is an exaggerated innate immune response in CF airways, available data indicate there is likely to be little difference in intrinsic inflammatory properties between normal and CF airway epithelia. However, this issue may not be resolved until experiments have been performed with properly paired CF and CFTR-corrected cells or CFTR-expressing cells treated with a specific CFTR blocker (102, 110, 172) during exposure to *P. aeruginosa* and to agonists that activate CFTR. The most likely models to explain altered inflammatory signaling in CF involve the effects of the absence of CFTR's anion channel function on ASL composition and volume, which secondarily alter cellular signaling. A smaller ASL volume in CF would concentrate proinflammatory factors like ATP, bradykinin, and epithelial-derived cytokines that could activate or synergize with TLR-MAPK-NF- κ B signaling. An acidic and/or oxidized ASL in CF resulting from reduced secretion of HCO_3^- or reduced GSH could also affect cell pH and/or redox, thereby altering cell signaling. Cytosolic redox might also be altered by increased O_2 consumption by CF cells, and the resulting hypoxia and altered redox could regulate signaling. The absence of CFTR hyperpolarizes V_{bl} , and this effect may increase Ca^{2+} entry into the cells. Increases in Ca_i alone appear to be sufficient to weakly activate NF- κ B, but larger Ca_i -induced activations of NF- κ B occur when the cells are simultaneously exposed to flagellin. The hyperinflammatory effect of CF on Ca_i and NF- κ B signaling would be most prominently expressed during exposure to both *P. aeruginosa* and also endocrine, paracrine or nervous agonists that activate Ca^{2+} signaling in the airway epithelia.

ACKNOWLEDGMENTS

I thank Horst Fischer, Kevin Foskett, Paul McCray, William Reenstra, and an anonymous reviewer for suggestions for improving the manuscript.

GRANTS

Work in this laboratory has been supported by the National Institutes of Health, the Cystic Fibrosis Foundation, Cystic Fibrosis Research, Inc., California Tobacco-Related Disease Research Program, and the Hawn Fund.

REFERENCES

1. Adamo R, Sokol S, Soong G, Gomez MI, and Prince A. *Pseudomonas aeruginosa* flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. *Am J Respir Cell Mol Biol* 30: 627–634, 2004.
2. Akira S and Takeda K. Toll-like receptor signalling. *Nat Rev Immunol* 4: 499–511, 2004.
3. Aldallal N, McNaughton EE, Manzel LJ, Richards AM, Zabner J, Ferkol TW, and Look DC. Inflammatory response in airway epithelial cells isolated from patients with cystic fibrosis. *Am J Respir Crit Care Med* 166: 1248–1256, 2002.
4. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, Frees K, Watt JL, and Schwartz DA. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. *Nat Genet* 25: 187–191, 2000.
5. Armstrong DS, Grimwood K, Carlin JB, Carzino R, Gutierrez JP, Hull J, Olinsky A, Phelan EM, Robertson CF, and Phelan PD. Lower airway inflammation in infants and young children with cystic fibrosis. *Am J Respir Crit Care Med* 156: 1197–1204, 1997.
6. Babnigg G, Heller B, and Villereal ML. Cell-to-cell variation in store-operated calcium entry in HEK-293 cells and its impact on the interpretation of data from stable clones expressing exogenous calcium channels. *Cell Calcium* 27: 61–73, 2000.
7. Baeuerle PA and Baltimore D. NF- κ B: ten years after. *Cell* 87: 13–20, 1995.
8. Ballard ST and Inglis SK. Liquid secretion properties of airway submucosal glands. *J Physiol* 556: 1–10, 2004.
9. Barasch J, Kiss B, Prince A, Saiman L, Gruenert D, and al-Awqati Q. Defective acidification of intracellular organelles in cystic fibrosis. *Nature* 352: 70–73, 1991.
10. Becker MN, Sauer MS, Muhlebach MS, Hirsh AJ, Wu Q, Verghese MW, and Randell SH. Cytokine secretion by cystic fibrosis airway epithelial cells. *Am J Respir Crit Care Med* 169: 645–653, 2004.
11. Bennett WD, Olivier KN, Zeman KL, Hohneker KW, Boucher RC, and Knowles MR. Effect of uridine 5'-triphosphate plus amiloride on mucociliary clearance in adult cystic fibrosis. *Am J Respir Crit Care Med* 153: 1796–1801, 1996.
12. Bensalem N, Ventura AP, Vallee B, Lipecka J, Tondelier D, Davezac N, Santos AD, Perretti M, Fajac A, Sermet-Gaudelus I, Renouil M, Lesure JF, Halgand F, Laprevote O, and Edelman A. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. *Mol Cell Proteomics* 4: 1591–1601, 2005.
13. Bishop C, Hudson VM, Hilton SC, and Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. *Chest* 127: 308–317, 2005.
14. Blaug S, Hybiske K, Cohn J, Firestone GL, Machen TE, and Miller SS. ENaC- and CFTR-dependent ion and fluid transport in mammary epithelia. *Am J Physiol Cell Physiol* 281: C633–C642, 2001.
15. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Hilliard JB, and Berger M. Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokine interleukin-10, which is downregulated in cystic fibrosis. *Am J Respir Cell Mol Biol* 13: 257–261, 1995.
16. Bonfield TL, Konstan MW, and Berger M. Altered respiratory epithelial cell cytokine production in cystic fibrosis. *J Allergy Clin Immunol* 104: 72–78, 1999.
17. Boucher RC, Stutts MJ, Knowles MR, Cantley L, and Gatzky JT. Na^+ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation. *J Clin Invest* 78: 1245–1252, 1986.
18. Bresser P, Out TA, van Alphen L, Jansen HM, and Lutter R. Airway inflammation in nonobstructive and obstructive chronic bronchitis with chronic *haemophilus influenzae* airway infection. Comparison with non-infected patients with chronic obstructive pulmonary disease. *Am J Respir Crit Care Med* 162: 947–952, 2000.

20. Brockhausen I, Vavasseur F, and Yang X. Biosynthesis of mucin type O-glycans: lack of correlation between glycosyltransferase and sulfotransferase activities and CFTR expression. *Glycoconj J* 18: 685–697, 2001.
21. Bruzzese E, Riaia V, Baudiello G, Polito G, Buccigrossi V, Formicola V, and Guarino A. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. *Aliment Pharmacol Ther* 20: 813–819, 2004.
22. Bryan R, Kube D, Perez A, Davis PB, and Prince A. Overproduction of the CFTR R-domain leads to increased levels of asialoGM1 and increased *P. aeruginosa* binding by epithelial cells. *Am J Respir Cell Mol Biol* 19: 269–277, 1998.
23. Carrabino S, Carpani D, Livraghi A, Di Cicco M, Costantini D, Copreni E, Colombo C, and Conese M. Dysregulated interleukin-8 secretion and NF- κ B activity in human cystic fibrosis nasal epithelial cells. *J Cyst Fibros* 5: 113–119, 2006.
24. Chandel NS, Maltepe E, Goldwasser E, Mathieu CE, Simon MC, and Schumacker PT. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. *Proc Natl Acad Sci USA* 95: 11715–11720, 1998.
25. Chandel NS, McClintock DS, Feliciano CE, Wood TM, Melendez JA, Rodriguez AM, and Schumacker PT. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 during hypoxia: a mechanism of O₂ sensing. *J Biol Chem* 275: 25130–25138, 2000.
26. Chandy G, Grabe M, Moore HP, and Machen TE. Proton leak and CFTR in regulation of Golgi pH in respiratory epithelial cells. *Am J Physiol Cell Physiol* 281: C908–C921, 2001.
27. Cheng SH, Gregory RJ, Marshall J, Paul S, Souza DW, White GA, O’Riordan CR, and Smith AE. Defective intracellular transport and processing of CFTR is the molecular basis of most cystic fibrosis. *Cell* 63: 827–834, 1990.
28. Clapham DE. TRP channels as cellular sensors. *Nature* 426: 517–524, 2003.
29. Coakley RD, Grubb BR, Paradiso AM, Gatzky JT, Johnson LG, Kreda SM, O’Neal WK, and Boucher RC. Abnormal surface liquid pH regulation by cultured cystic fibrosis bronchial epithelium. *Proc Natl Acad Sci USA* 100: 16083–16088, 2003.
30. Cobb LM, Mychaleckyj JC, Wozniak DJ, and Lopez-Boado YS. *Pseudomonas aeruginosa* flagellin and alginate elicit very distinct gene expression patterns in airway epithelial cells: implications for cystic fibrosis disease. *J Immunol* 173: 5659–5670, 2004.
31. Cole AM, Dewan P, and Ganz T. Innate antimicrobial activity of nasal secretions. *Infect Immun* 67: 3267–3275, 1999.
32. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, and Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. *Am J Respir Crit Care Med* 165: 904–10, 2002.
33. Darling KE, Dewar A, and Evans TJ. Role of the cystic fibrosis transmembrane conductance regulator in internalization of *Pseudomonas aeruginosa* by polarized respiratory epithelial cells. *Cell Microbiol* 6: 521–537, 2004.
- 33a. De Bentzmann S, Roger P, Dupuit F, Bajolet-Laudinat O, Fuchey C, Plotkowski MC, and Puchelle E. Asialo GM1 is a receptor for *Pseudomonas aeruginosa* adherence to regenerating respiratory epithelial cells. *Infect Immun* 64: 1582–1588, 1996.
34. Denning GM, Wollenweber LA, Railsback MA, Cox CD, Stoll LL, and Britigan BE. *Pseudomonas pyocyanin* increases interleukin-8 expression by human airway epithelial cells. *Infect Immun* 66: 5777–5784, 1998.
35. DiMango E, Zar HJ, Bryan R, and Prince A. Diverse *Pseudomonas aeruginosa* gene products stimulate respiratory epithelial cells to produce interleukin-8. *J Clin Invest* 96: 2204–2210, 1995.
36. DiMango E, Ratner AJ, Bryan R, Tabibi S, and Prince A. Activation of NF- κ B by adherent *Pseudomonas aeruginosa* in normal and cystic fibrosis respiratory epithelial cells. *J Clin Invest* 101: 2598–2605, 1998.
37. Dolmetsch RE, Lewis RS, Goodnow CC, and Healy JL. Differential activation of transcription factors induced by Ca²⁺ response amplitude and duration. *Nature* 386: 855–858, 1997.
38. Dosanjh A, Lencer W, Brown D, Ausiello DA, and Stow JL. Heterologous expression of Δ F508 CFTR results in decreased sialylation of membrane glycoconjugates. *Am J Physiol Cell Physiol* 266: C360–C366, 1994.
39. Dunn KW, Park J, Semrad CE, Gelman DL, Shevell T, and McGraw TE. Regulation of endocytic trafficking and acidification are independent of the cystic fibrosis transmembrane regulator. *J Biol Chem* 269: 5336–5345, 1994.
40. Ehring GR, Kerschbaum HH, Eder C, Neben AL, Fanger CM, Khoury RM, Negulescu PA, and Cahalan MD. A nongenomic mechanism for progesterone-mediated immunosuppression: inhibition of K⁺ channels, Ca²⁺ signaling, and gene expression in T lymphocytes. *J Exp Med* 188: 1593–1602, 1998.
41. Eidelman O, Srivastava M, Zhang J, Leighton X, Murtie J, Jozwik C, Jacobson K, Weinstein DL, Metcalf EL, and Pollard HB. Control of the proinflammatory state in cystic fibrosis lung epithelial cells by genes from the TNF- α /NF- κ B pathway. *Mol Med* 7: 523–534, 2001.
42. Engelhardt JF, Zepeda M, Cohn JA, Yankaskas JR, and Wilson JM. Expression of the cystic fibrosis gene in adult human lung. *J Clin Invest* 93: 737–749, 1994.
43. Estell K, Braunstein G, Tucker T, Varga K, Collawn JF, and Schwiebert LM. Plasma membrane CFTR regulates RANTES expression via its C-terminal PDZ-interacting motif. *Mol Cell Biol* 23: 594–606, 2003.
44. Fischer H, Illek B, Negulescu PA, Clauss W, and Machen TE. Carbachol-activated Ca entry into HT-29 cells is regulated by both membrane potential and cell volume. *Proc Natl Acad Sci USA* 89: 1438–1442, 1992.
45. Fischer H, Widdicombe JH, and Illek B. Acid secretion and proton conductance in human airway epithelium. *Am J Physiol Cell Physiol* 282: C736–C743, 2002.
46. Fleiszig SM, Evans DJ, Do N, Vallas V, Shin S, and Mostov KE. Epithelial cell polarity affects susceptibility to *Pseudomonas aeruginosa* invasion and cytotoxicity. *Infect Immun* 65: 2861–2867, 1997.
47. Gao L, Kim KJ, Yankaskas JB, and Forman HJ. Abnormal glutathione transport in cystic fibrosis airway epithelia. *Am J Physiol Lung Cell Mol Physiol* 277: L113–L118, 1999.
48. Gelman MS, Kannegaard ES, and Kopito RR. A principal role for the proteasome in endoplasmic reticulum-associated degradation of misfolded intracellular cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 277: 11709–11714, 2002.
49. Gibson GA, Hill WG, and Weisz OA. Evidence against the acidification hypothesis in cystic fibrosis. *Am J Physiol Cell Physiol* 279: C1088–C1099, 2000.
50. Gomez MI, Lee A, Reddy B, Muir A, Soong G, Pitt A, Cheung A, and Prince A. *Staphylococcus aureus* protein A induces airway epithelial inflammatory responses by activating TNFR1. *Nat Med* 10: 842–848, 2004.
51. Grassme H, Jendrossek V, Riehle A, von Kurthy G, Berger J, Schwarz H, Weller M, Kolesnick R, and Gulbins E. Host defense against *Pseudomonas aeruginosa* requires ceramide-rich membrane rafts. *Nat Med* 9: 322–330, 2003.
52. Greene CM, Carroll TP, Smith SG, Taggart CC, Devaney J, Griffin S, O’Neill SJ, and McElvaney NG. TLR-induced inflammation in cystic fibrosis and non-cystic fibrosis airway epithelial cells. *J Immunol* 174: 1638–1646, 2005.
53. Guerra L, Fanelli T, Favia M, Riccardi SM, Busco G, Cardone RA, Carrabino S, Weinman EJ, Reshkin SJ, Conese M, and Casavola V. Na⁺/H⁺ exchanger regulatory factor isoform 1 overexpression modulates cystic fibrosis transmembrane conductance regulator (CFTR) expression and activity in human airway 16HBE14o– cells and rescues Δ F508 CFTR functional expression in cystic fibrosis cells. *J Biol Chem* 280: 40925–40933, 2005.
54. Hallows KR, Fitch AC, Richardson CA, Reynolds PR, Clancy JP, Dagher PC, Witters LA, Kolls JK, and Pilewski JM. Up-regulation of AMP-activated kinase by dysfunctional cystic fibrosis transmembrane conductance regulator in cystic fibrosis airway epithelial cells mitigates excessive inflammation. *J Biol Chem* 281: 4231–4241, 2006.
55. Hallows KR, Kobinger GP, Wilson JM, Witters LA, and Foskett JK. Physiological modulation of CFTR activity by AMP-activated protein kinase in polarized T84 cells. *Am J Physiol Cell Physiol* 284: C1297–C1308, 2003.
56. Hallows KR, McCane JE, Kemp BE, Witters LA, and Foskett JK. Regulation of channel gating by AMP-activated protein kinase modulates cystic fibrosis transmembrane conductance regulator activity in lung submucosal cells. *J Biol Chem* 278: 998–1004, 2003.
57. Hallows KR, Raghuram V, Kemp BE, Witters LA, and Foskett JK. Inhibition of cystic fibrosis transmembrane conductance regulator by

- novel interaction with the metabolic sensor AMP-activated protein kinase. *J Clin Invest* 105: 1711–1721, 2000.
58. **Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM, and Aderem A.** The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. *Nature* 410: 1099–1103, 2001.
 59. **Hertz CJ, Wu Q, Porter EM, Zhang YJ, Weismuller KH, Godowski PJ, Ganz T, Randell SH, and Modlin RL.** Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human β -defensin-2. *J Immunol* 171: 6820–6826, 2003.
 60. **Hirsila M, Koivunen P, Gunzler V, Kivirikko KI, and Myllyharju J.** Characterization of the human prolyl 4-hydroxylases that modify the hypoxia-inducible factor. *J Biol Chem* 278: 30772–30780, 2003.
 61. **Homma T, Kato A, Hashimoto N, Batchelor J, Yoshikawa M, Imai S, Wakiguchi H, Saito H, and Matsumoto K.** Corticosteroid and cytokines synergistically enhance toll-like receptor 2 expression in respiratory epithelial cells. *Am J Respir Cell Mol Biol* 31: 463–469, 2004.
 62. **Hudson VM.** New insights into the pathogenesis of cystic fibrosis: pivotal role of glutathione system dysfunction and implications for therapy. *Treat Respir Med* 3: 353–363, 2004.
 63. **Hybiske K, Ichikawa JK, Huang V, Lory SJ, and Machen TE.** Cystic fibrosis airway epithelial cell polarity and bacterial flagellin determine host response to *Pseudomonas aeruginosa*. *Cell Microbiol* 6: 49–63, 2004.
 64. **Illek B, Yankaskas JR, and Machen TE.** cAMP and genistein stimulate HCO_3^- conductance through CFTR in human airway epithelia. *Am J Physiol Lung Cell Mol Physiol* 272: L752–L761, 1997.
 65. **Imberty A, Wimmerova M, Mitchell EP, and Gilboa-Garber N.** Structures of the lectins from *Pseudomonas aeruginosa*: insight into the molecular basis for host glycan recognition. *Microbes Infect* 6: 221–228, 2004.
 66. **Imundo L, Barasch J, Prince A, and Al-Awqati Q.** Cystic fibrosis epithelial cells have a receptor for pathogenic bacteria on their apical surface. *Proc Natl Acad Sci USA* 92: 3019–3023, 1995.
 67. **Inglis SK, Wilson SM, and Olver RE.** Secretion of acid and base equivalents by intact distal airways. *Am J Physiol Lung Cell Mol Physiol* 284: L855–L862, 2003.
 68. **Jacob T, Lee RJ, Engel JN, and Machen TE.** Modulation of cytosolic Ca^{2+} concentration in airway epithelial cells by *Pseudomonas aeruginosa*. *Infect Immun* 70: 6399–6408, 2002.
 69. **Jayaraman S, Joo NS, Reitz B, Wine JJ, and Verkman AS.** Submucosal gland secretions in airways from cystic fibrosis patients have normal $[\text{Na}^+]$ and pH but elevated viscosity. *Proc Natl Acad Sci USA* 98: 8119–8123, 2001.
 70. **Jayaraman S, Song Y, and Verkman AS.** Airway surface liquid pH in well-differentiated airway epithelial cell cultures and mouse trachea. *Am J Physiol Cell Physiol* 281: C1504–C1511, 2001.
 71. **Jia HP, Kline JN, Penisten A, Apicella MA, Gioannini TL, Weiss J, and McCray PB Jr.** Endotoxin responsiveness of human airway epithelia is limited by low expression of MD-2. *Am J Physiol Lung Cell Mol Physiol* 287: L428–L437, 2004.
 72. **Jiang X, Hill WG, Pilewski JM, and Weisz OA.** Glycosylation differences between a cystic fibrosis and rescued airway cell line are not CFTR dependent. *Am J Physiol Lung Cell Mol Physiol* 273: L913–L920, 1997.
 73. **Joo NS, Irokawa T, Robbins RC, and Wine JJ.** Hyposecretion, not hyperabsorption, is the basic defect of cystic fibrosis airway glands. *J Biol Chem* 281: 7392–7398, 2006.
 74. **Joseph T, Look D, and Ferkol T.** NF- κ B activation and sustained IL-8 gene expression in primary cultures of cystic fibrosis airway epithelial cells stimulated with *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol* 288: L471–L479, 2005.
 75. **Kabe Y, Ando K, Hirao S, Yoshida M, and Handa H.** Redox regulation of NF- κ B activation: distinct redox regulation between the cytoplasm and the nucleus. *Antioxid Redox Signal* 7: 395–403, 2005.
 76. **Karp CL, Flick LM, Park KW, Softic S, Greer TM, Keledjian R, Yang R, Uddin J, Guggino WB, Atabani SF, Belkaid Y, Xu Y, Whitsett JA, Accurso FJ, Wills-Karp M, and Petasis NA.** Defective lipoxin-mediated anti-inflammatory activity in the cystic fibrosis airway. *Nat Immun* 5: 388–392, 2004.
 77. **Kaur S, Norkina O, Ziemer D, Samuelson LC, and De Lisle RC.** Acidic duodenal pH alters gene expression in the cystic fibrosis mouse pancreas. *Am J Physiol Gastrointest Liver Physiol* 287: G480–G490, 2004.
 78. **Kelley TJ and Drumm ML.** Inducible nitric oxide synthase expression is reduced in cystic fibrosis murine and human airway epithelial cells. *J Clin Invest* 102: 1200–1207, 1998.
 79. **Kelley TJ and Elmer HL.** In vivo alterations of IFN regulatory factor-1 and PIAS1 protein levels in cystic fibrosis epithelium. *J Clin Invest* 106: 403–410, 2000.
 80. **Khan TZ, Wagener JS, Bost T, Martinez J, Accurso FJ, and Riches DW.** Early pulmonary inflammation in infants with cystic fibrosis. *Am J Respir Crit Care Med* 151: 1075–1082, 1995.
 81. **Kim SK, Woodcroft KJ, Oh SJ, Abdelmegeed MA, and Novak RF.** Role of mechanical and redox stress in activation of mitogen-activated protein kinases in primary cultured rat hepatocytes. *Biochem Pharmacol* 70: 1785–1795, 2005.
 82. **Knowles MR and Boucher RC.** Mucus clearance as a primary innate defense mechanism for mammalian airways. *J Clin Invest* 109: 571–577, 2002.
 83. **Koch A, Giembycz M, Ito K, Lim S, Jazrawi E, Barnes PJ, Adcock I, Erdmann E, and Chung KF.** Mitogen-activated protein kinase modulation of nuclear factor- κ B-induced granulocyte macrophage-colony-stimulating factor release from human alveolar macrophages. *Am J Respir Cell Mol Biol* 30: 342–349, 2004.
 84. **Konstan MW and Davis PB.** Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. *Adv Drug Delivery Res* 54: 1409–1423, 2002.
 85. **Kopito RR.** Biosynthesis and degradation of CFTR. *Physiol Rev* 79: S167–S173, 1999.
 86. **Kowalski MP and Pier GB.** Localization of cystic fibrosis transmembrane conductance regulator to lipid rafts of epithelial cells is required for *Pseudomonas aeruginosa*-induced cellular activation. *J Immunol* 172: 418–425, 2004.
 87. **Kreda SM, Mall M, Mengos A, Rochelle L, Yankaskas J, Riordan JR, and Boucher RC.** Characterization of wild-type and Δ F508 cystic fibrosis transmembrane regulator in human respiratory epithelia. *Mol Biol Cell* 16: 2154–2167, 2005.
 88. **Kreiselmeier NE, Kraynack NC, Corey DA, and Kelley TJ.** Statin-mediated correction of STAT1 signaling and inducible nitric oxide synthase expression in cystic fibrosis epithelial cells. *Am J Physiol Lung Cell Mol Physiol* 285: L1286–L1295, 2003.
 89. **Krouse ME, Talbott JF, Lee MM, Joo NS, and Wine JJ.** Acid and base secretion in the Calu-3 model of human serous cells. *Am J Physiol Lung Cell Mol Physiol* 287: L1274–L1283, 2004.
 90. **Kube D, Sontic U, Fletcher D, and Davis PB.** Proinflammatory cytokine responses to *P. aeruginosa* infection in human airway epithelial cell lines. *Am J Physiol Lung Cell Mol Physiol* 280: L493–L502, 2001.
 91. **Kyle H, Ward JP, and Widdicombe JG.** Control of pH of airway surface liquid of the ferret trachea in vitro. *J Appl Physiol* 68: 135–140, 1990.
 92. **Lamblin G, Degroote S, Perini JM, Delmotte P, Scharfman A, Davril M, Lo-Guidice JM, Houdret N, Dumur V, Klein A, and Rousse P.** Human airway mucin glycosylation: a combinatorial of carbohydrate determinants which vary in cystic fibrosis. *Glycoconj J* 18: 661–684, 2001.
 93. **Lando D, Peet DJ, Whelan DA, Gorman JJ, and Whitelaw ML.** Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. *Science* 295: 858–861, 2002.
 94. **Lee A, Chow D, Tseng W, Haus B, Evans D, Fleiszig S, Chandy G, and Machen TE.** Airway epithelial tight junctions and binding and cytotoxicity of *Pseudomonas aeruginosa*. *Am J Physiol Lung Cell Mol Physiol* 277: L204–L217, 1999.
 95. **Lee MC, Penland CM, Widdicombe JH, and Wine JJ.** Evidence that Calu-3 human airway cells secrete bicarbonate. *Am J Physiol Lung Cell Mol Physiol* 274: L450–L453, 1998.
 96. **Leir SH, Parry S, Palma-Pallag T, Evans J, Morris HR, Dell A, and Harris A.** Mucin glycosylation and sulphation in airway epithelial cells is not influenced by cystic fibrosis transmembrane conductance regulator expression. *Am J Respir Cell Mol Biol* 32: 453–461, 2005.
 97. **Li J, Dai Z, Jana D, Callaway DJ, and Bu Z.** Ezrin controls the macromolecular complexes formed between an adapter protein Na^+/H^+ exchanger regulatory factor and the cystic fibrosis transmembrane conductance regulator. *J Biol Chem* 280: 37634–37643, 2005.
 98. **Li X, Li S, Xu Z, Lou MF, Anding P, Liu D, Roy SK, and Rozanski GJ.** Redox control of K^+ channel remodeling in rat ventricle. *J Mol Cell Cardiol* 40: 339–349, 2006.

99. Li Y, Wang W, Parker W, and Clancy JP. Adenosine regulation of CFTR through prostenoids in airway epithelia. *Am J Respir Cell Mol Biol* 34: 600–608, 2006.
100. Lindstrom M, Camner P, Falk R, Hjelte L, Philipson K, and Svartengren M. Long-term clearance from small airways in patients with cystic fibrosis. *Eur Respir J* 25: 317–323, 2005.
101. Linsdell P and Hanrahan JW. Glutathione permeability of CFTR. *Am J Physiol Cell Physiol* 275: C323–C326, 1998.
102. Ma T, Thiagarajah JR, Yang H, Sonawane ND, Folli C, Galiotta LJ, and Verkman AS. Thiazolidinone CFTR inhibitor identified by high-throughput screening blocks cholera toxin-induced intestinal fluid secretion. *J Clin Invest* 110: 1651–1658, 2002.
103. Machen T and Fu Z. Ca²⁺ synergism in flagellin-activated innate immune responses of airway epithelia. *Ped Pulmon*. In press.
104. Machen TE, Leigh MJ, Taylor C, Kimura T, Asano S, and Moore HP. pH of TGN and recycling endosomes of H⁺/K⁺-ATPase-transfected HEK-293 cells: implications for pH regulation in the secretory pathway. *Am J Physiol Cell Physiol* 285: C205–C214, 2003.
105. Matos TJ, Duarte CB, Goncalo M, and Lopes MC. Role of oxidative stress in ERK and p38 MAPK activation induced by the chemical sensitizer DNFB in a fetal skin dendritic cell line. *Immunol Cell Biol* 83: 607–614, 2005.
106. McNamara N and Basbaum C. Mechanism by which bacterial flagellin stimulates host mucin production. *Adv Exp Med Biol* 506: 269–273, 2002.
107. McNamara N, Khong A, McKemy D, Caterina M, Boyer J, Julius D, and Basbaum C. ATP transduces signals from ASGM1, a glycolipid that functions as a bacterial receptor. *Proc Natl Acad Sci USA* 98: 9086–9091, 2001.
108. McNamara N, Gallup M, Sucher A, Maltseva I, McKemy D, and Basbaum C. ASIALOGM1 and TLR5 cooperate in flagellin-induced nucleotide signaling to activate ERK1/2. *Am J Respir Cell Mol Biol*. In Press.
109. McShane D, Davies JC, Wodehouse T, Bush A, Geddes D, and Alton EW. Normal nasal mucociliary clearance in CF children: evidence against a CFTR-related defect. *Eur Respir J* 24: 95–100, 2004.
110. Muanprasat C, Sonawane ND, Salinas D, Taddei A, Galiotta LJ, and Verkman AS. Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. *J Gen Physiol* 124: 125–137, 2004.
111. Muhlebach MS, Stewart PW, Leigh MW, and Noah TL. Quantification of inflammatory responses to bacteria in young cystic fibrosis and control patients. *Am J Respir Crit Care Med* 160: 186–191, 1999.
112. Muir A, Soong G, Sokol S, Reddy B, Gomez MI, Van Heeckeren A, and Prince A. Toll-like receptors in normal and cystic fibrosis airway epithelial cells. *Am J Respir Cell Mol Biol* 30: 777–783, 2004.
113. Negulescu PA and Machen TE. Cellular ion activities and membrane transport in parietal cells measured with fluorescent probes. *Methods Enzymol* 192: 38–81, 1990.
114. Negulescu PA, Shastri N, and Cahalan MD. Intracellular calcium dependence of gene expression in single T lymphocytes. *Proc Natl Acad Sci USA* 91: 2873–2877, 1994.
115. Noah TL, Black HR, Cheng PW, Wood RE, and Leigh MW. Nasal and bronchoalveolar lavage fluid cytokines in early cystic fibrosis. *J Infect Dis* 175: 638–647, 1997.
116. Norkina O, Burnett TG, and De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. *Infect Immun* 72: 6040–6049, 2004.
117. Norkina O, Kaur S, Ziemer D, and De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. *Am J Physiol Gastrointest Liver Physiol* 286: G1032–G1041, 2004.
118. Pahl HL and Baeuerle PA. Activation of NF- κ B by ER stress requires both Ca²⁺ and reactive oxygen intermediates as messengers. *FEBS Lett* 392: 129–136, 1996.
119. Pahl HL, Sester M, Burgert HG, and Baeuerle PA. Activation of transcription factor NF- κ B by the adenovirus E3/19K protein requires its ER retention. *J Cell Biol* 132: 511–522, 1996.
120. Paradiso AM, Coakley RD, and Boucher RC. Polarized distribution of HCO₃⁻ transport in human normal and cystic fibrosis nasal epithelia. *J Physiol* 548: 203–218, 2003.
121. Paradiso AM, Ribeiro CM, and Boucher RC. Polarized signaling via purinoceptors in normal and cystic fibrosis airway epithelia. *J Gen Physiol* 117: 53–67, 2001.
122. Patil C and Walter P. Intracellular signaling from the endoplasmic reticulum to the nucleus: the unfolded protein response in yeast and mammals. *Curr Opin Cell Biol* 13: 349–355, 2001.
123. Peckham D, Holland E, Range S, and Knox AJ. Na⁺/K⁺ ATPase in lower airway epithelium from cystic fibrosis and non-cystic-fibrosis lung. *Biochem Biophys Res Commun* 232: 464–468, 1997.
124. Perez A and Davis PB. Gene profile changes after *Pseudomonas aeruginosa* exposure in immortalized airway epithelial cells. *J Struct Funct Genomics* 5: 179–194, 2004.
125. Perez-Vilar J and Boucher RC. Reevaluating gel-forming mucins' roles in cystic fibrosis lung disease. *Free Radic Biol Med* 37: 1564–1577, 2004.
126. Pier GB. Role of the cystic fibrosis transmembrane conductance regulator in innate immunity to *Pseudomonas aeruginosa* infections. *Proc Natl Acad Sci USA* 97: 8822–8828, 2000.
127. Pier GB. CFTR mutations and host susceptibility to *Pseudomonas aeruginosa* lung infection. *Curr Opin Microbiol* 5: 81–86, 2002.
128. Pier GB, Grout M, and Zaidi TS. Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of *Pseudomonas aeruginosa* from the lung. *Proc Natl Acad Sci USA* 94: 12088–12093, 1997.
129. Pier GB, Grout M, Zaidi TS, Olsen JC, Johnson LG, Yankaskas JR, and Goldberg JB. Role of mutant CFTR in hypersusceptibility of cystic fibrosis patients to lung infections. *Science* 271: 64–67, 1996.
130. Pizurki L, Morris MA, Chanson M, Solomon M, Pavirani A, Bouchardy I, and Suter S. Cystic fibrosis transmembrane conductance regulator does not affect neutrophil migration across cystic fibrosis airway epithelial monolayers. *Am J Pathol* 156: 1407–1416, 2000.
131. Poschet JF, Boucher JC, Tattersall L, Skidmore J, Van Dyke RW, and Deretic V. Molecular basis for defective glycosylation and *Pseudomonas* pathogenesis in cystic fibrosis lung. *Proc Natl Acad Sci USA* 98: 13972–13977, 2001.
132. Poulsen JH, Fischer H, Illek B, and Machen TE. Bicarbonate conductance and pH regulatory capability of CFTR. *Proc Natl Acad Sci USA* 91: 5340–5344, 1994.
133. Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, Auricchio S, and Londei M. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. *Pediatr Res* 47: 344–350, 2000.
134. Ramos HC, Rumbo M, and Sirard JC. Bacterial flagellins: mediators of pathogenicity and host immune responses in mucosa. *Trends Microbiol* 12: 509–517, 2004.
135. Ramphal R, McNiece MT, and Pollack FD. Adherence of *Pseudomonas aeruginosa* to injured cornea. A step in pathogenesis of corneal infections. *Ann Ophthalmol* 100: 1956–1958, 1981.
136. Ran H, Hassett DJ, and Lau GW. Human targets of *Pseudomonas aeruginosa* pyocyanin. *Proc Natl Acad Sci USA* 100: 14315–14320, 2003.
137. Ratner AJ, Bryan R, Weber A, Nguyen S, Barnes D, Pitt A, Gelber S, Cheung A, and Prince A. Cystic fibrosis pathogens activate Ca²⁺-dependent mitogen-activated protein kinase signaling pathways in airway epithelial cells. *J Biol Chem* 276: 19267–19275, 2001.
138. Ratner AJ, Lysenko ES, Paul MN, and Weiser JN. Synergistic proinflammatory responses induced by polymicrobial colonization of epithelial surfaces. *Proc Natl Acad Sci USA* 102: 3429–3434, 2005.
139. Reddy MM and Quinton PM. Altered electrical potential profile of human reabsorptive sweat duct cells in cystic fibrosis. *Am J Physiol Cell Physiol* 257: C722–C726, 1989.
140. Reid CJ, Burdick MD, Hollingsworth MA, and Harris A. CFTR expression does not influence glycosylation of an epitope-tagged MUC1 mucin in colon carcinoma cell lines. *Glycobiology* 9: 389–398, 1999.
141. Reiniger N, Ichikawa JK, and Pier GB. Influence of cystic fibrosis transmembrane conductance regulator on gene expression in response to *Pseudomonas aeruginosa* infection of human bronchial epithelial cells. *Infect Immun* 73: 6822–6830, 2005.
142. Reinlib L, Jefferson DJ, Marini FC, and Donowitz M. Abnormal secretagogue-induced intracellular free Ca²⁺ regulation in cystic fibrosis nasal epithelial cells. *Proc Natl Acad Sci USA* 89: 2955–2959, 1992.
143. Rhim AD, Stoykova L, Glick MC, and Scanlin TF. Terminal glycosylation in cystic fibrosis (CF): a review emphasizing the airway epithelial cell. *Glycoconj J* 18: 649–659, 2001.
144. Ribeiro CM, Paradiso AM, Carew MA, Shears SB, and Boucher RC. Cystic fibrosis airway epithelial Ca²⁺ signaling: the mechanism for the

- larger agonist-mediated Ca^{2+} signals in human cystic fibrosis airway epithelia. *J Biol Chem* 280: 10202–10209, 2005.
145. **Ribeiro CM, Paradiso AM, Schwab U, Perez-Vilar J, Jones L, O'Neal W, and Boucher RC.** Chronic airway infection/inflammation induces a Ca^{2+} -dependent hyperinflammatory response in human cystic fibrosis airway epithelia. *J Biol Chem* 280: 17798–17806, 2005.
 146. **Ribeiro CM, Paradiso AM, Livraghi A, and Boucher RC.** The mitochondrial barriers segregate agonist-induced calcium-dependent functions in human airway epithelia. *J Gen Physiol* 122: 377–387, 2003.
 147. **Rodgers HC, Pang L, Holland E, Corbett L, Range S, and Knox AJ.** Bradykinin increases IL-8 generation in airway epithelial cells via COX-2-derived prostanoids. *Am J Physiol Lung Cell Mol Physiol* 283: L612–L618, 2002.
 148. **Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Kehagia V, Jones GR, and Bruce KD.** Bacterial activity in cystic fibrosis lung infections. *Respir Res* 6: 49, 2005.
 149. **Rogers GB, Carroll MP, Serisier DJ, Hockey PM, Jones G, and Bruce KD.** Characterization of bacterial community diversity in cystic fibrosis lung infections by use of 16s ribosomal DNA terminal restriction fragment length polymorphism profiling. *J Clin Microbiol* 42: 5176–5178, 2004.
 150. **Rosenfeld M, Gibson RL, McNamara S, Emerson J, Burns JL, Castile R, Hiatt P, McCoy K, Wilson CB, Inglis A, Smith A, Martin TR, and Ramsey BW.** Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. *Pediatr Pulmonol* 32: 356–366, 2001.
 151. **Roum JH, Buhl R, McElvaney NG, Borok Z, and Crystal RG.** Systemic deficiency of glutathione in cystic fibrosis. *J Appl Physiol* 75: 2419–2424, 1993.
 152. **Sadikot RT, Blackwell TS, Christman JW, and Prince AS.** Pathogen-host interactions in *Pseudomonas aeruginosa* pneumonia. *Am J Respir Crit Care Med* 171: 1209–1223, 2005.
 153. **Saiman L and Prince AP.** *Aeruginosa* pili bind to asialoGM1 which is increased on the surface of cystic fibrosis epithelial cells. *J Clin Invest* 92: 1875–1880, 1993.
 154. **Sand P, Svenberg T, and Rydqvist B.** Carbachol induces oscillations in membrane potential and intracellular calcium in a colonic tumor cell line, HT-29. *Am J Physiol Cell Physiol* 273: C1186–C1193, 1997.
 155. **Scanlin TF and Glick MC.** Terminal glycosylation in cystic fibrosis. *Biochim Biophys Acta* 1455: 241–253, 1999.
 156. **Schapiro FB and Grinstein S.** Determinants of the pH of the Golgi complex. *J Biol Chem* 275: 21025–21032, 2000.
 157. **Schroedel C, McClintock DS, Budinger GR, and Chandel NS.** Hypoxic but not anoxic stabilization of HIF-1 requires mitochondrial reactive oxygen species. *Am J Physiol Lung Cell Mol Physiol* 283: L922–L931, 2002.
 158. **Schulz BL, Sloane AJ, Robinson LJ, Sebastian LT, Glanville AR, Song Y, Verkman AS, Harry JL, Packer NH, and Karlsson NG.** Mucin glycosylation changes in cystic fibrosis lung disease are not manifest in submucosal gland secretions. *Biochem J* 387: 911–919, 2005.
 159. **Schwiebert LM, Estell K, and Propst SM.** Chemokine expression in CF epithelia: implications for the role of CFTR in RANTES expression. *Am J Physiol Cell Physiol* 276: C700–C710, 1999.
 160. **Seksek O, Biwersi J, and Verkman AS.** Evidence against defective *trans*-Golgi acidification in cystic fibrosis. *J Biol Chem* 271: 15542–15548, 1996.
 161. **Shori DK, Kariyawasam HH, Knight RA, Hodson ME, Genter T, Hansen J, Koch C, and Kalogeridis A.** Sulphation of the salivary mucin MG1 (MUC-5B) is not correlated to the degree of its sialylation and is unaffected by cystic fibrosis. *Pflügers Arch* 443: S50–S4, 2001.
 162. **Smith RS, Fedyk ER, Springer TA, Mukaida N, Iglewski BH, and Phipps RP.** IL-8 production in human lung fibroblasts and epithelial cells activated by the *Pseudomonas* autoinducer N-3-oxododecanoyl homoserine lactone is transcriptionally regulated by NF- κ B and activator protein-2. *J Immunol* 167: 366–374, 2001.
 163. **Smith JJ and Welsh MJ.** cAMP stimulates bicarbonate secretion across normal, but not cystic fibrosis airway epithelia. *J Clin Invest* 89: 1148–1153, 1992.
 164. **Smyth RL, Croft NM, O'Hea U, Marshall TG, and Ferguson A.** Intestinal inflammation in cystic fibrosis. *Arch Dis Child* 82: 394–399, 2000.
 165. **Song Y, Thiagarajah J, and Verkman AS.** Sodium and chloride concentrations, pH, and depth of airway surface liquid in distal airways. *J Gen Physiol* 122: 511–519, 2003.
 166. **Srivastava M, Eidelman O, Zhang J, Pawletz C, Caohuy H, Yang Q, Jacobson KA, Heldman E, Huang W, Jozwik C, Pollard BS, and Pollard HB.** Digitoxin mimics gene therapy with CFTR and suppresses hypersecretion of IL-8 from cystic fibrosis lung epithelial cells. *Proc Natl Acad Sci USA* 101: 7693–7698, 2004.
 167. **Srivastava M, Eidelman O, and Pollard HB.** Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis. *Mol Med* 5: 753–767, 1999.
 168. **Steagall WK, Elmer HL, Brady KG, and Kelley TJ.** Cystic fibrosis transmembrane conductance regulator-dependent regulation of epithelial inducible nitric oxide synthase expression. *Am J Respir Cell Mol Biol* 22: 45–50, 2000.
 169. **Stutts MJ, Knowles MR, Gatzky JT, and Boucher RC.** Oxygen consumption and ouabain binding sites in cystic fibrosis nasal epithelium. *Pediatr Res* 20: 1316–1320, 1986.
 170. **Sun F, Hug MJ, Lewarchik CM, Yun CH, Bradbury NA, and Frizzell RA.** E3KARP mediates the association of ezrin and protein kinase A with the cystic fibrosis transmembrane conductance regulator in airway cells. *J Biol Chem* 275: 29539–29546, 2000.
 171. **Tabary O, Escotte S, Couetil JP, Hubert D, Dusser D, Puchelle E, and Jacquot J.** High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I κ B kinase- α pathway in response to extracellular NaCl content. *J Immunol* 164: 3377–3384, 2000.
 172. **Taddei A, Folli C, Zegarra-Moran O, Fanen P, Verkman AS, and Galiotta LJ.** Altered channel gating mechanism for CFTR inhibition by a high-affinity thiazolidinone blocker. *FEBS Lett* 558: 52–56, 2004.
 173. **Tamada T, Hug MJ, Frizzell RA, and Bridges RJ.** Microelectrode and impedance analysis of anion secretion in Calu-3 cells. *JOP* 2: 219–228, 2001.
 174. **Tchilibon S, Zhang J, Yang Q, Eidelman O, Kim H, Caohuy H, Jacobson KA, Pollard BS, and Pollard HB.** Amphiphilic pyridinium salts block TNF α /NF κ B signaling and constitutive hypersecretion of interleukin-8 (IL-8) from cystic fibrosis lung epithelial cells. *Biochem Pharmacol* 70: 381–393, 2005.
 175. **Thomsson KA, Hinojosa-Kurtzberg M, Axelsson KA, Domino SE, Lowe JB, Gendler SJ, and Hansson GC.** Intestinal mucins from cystic fibrosis mice show increased fucosylation due to an induced Fuc α 1–2 glycosyltransferase. *Biochem J* 367: 609–616, 2002.
 176. **Tirouvanziam R, de Bentzmann S, Hubeau C, Hinrasky J, Jacquot J, Peault B, and Puchelle E.** Inflammation and infection in naive human cystic fibrosis airway grafts. *Am J Respir Cell Mol Biol* 23: 121–127, 2000.
 177. **Trout L, King M, Feng W, Inglis SK, and Ballard ST.** Inhibition of airway liquid secretion and its effect on the physical properties of airway mucus. *Am J Physiol Lung Cell Mol Physiol* 274: L258–L263, 1998.
 178. **Travassos LH, Carneiro LA, Girardin SE, Boneca IG, Lemos R, Bozza MT, Domingues RC, Coyle AJ, Bertin J, Philpott DJ, and Plotkowski MC.** Nod1 participates in the innate immune response to *Pseudomonas aeruginosa*. *J Biol Chem* 280: 36714–36718, 2005.
 179. **Tseng J, Do J, Widdicombe JH, and Machen TE.** Innate immune responses to *P. aeruginosa* flagellin, TNF- α and IL-1 β . *Am J Physiol Cell Physiol* 290: C678–C690, 2006.
 180. **Ulrich M, Herbert S, Berger J, Bellon G, Louis D, Munker G, and Doring G.** Localization of *Staphylococcus aureus* in infected airways of patients with cystic fibrosis and in a cell culture model of *S. aureus* adherence. *Am J Respir Cell Mol Biol* 19: 83–91, 1998.
 181. **Urban TA, Griffith A, Torok AM, Smolkin ME, Burns JL, and Goldberg JB.** Contribution of *Burkholderia cenocepacia* flagella to infectivity and inflammation. *Infect Immun* 72: 5126–5134, 2004.
 182. **Uyekubo SN, Fischer H, Maminishkis A, Illek B, Miller SS, and Widdicombe JH.** cAMP-dependent absorption of chloride across airway epithelium. *Am J Physiol Lung Cell Mol Physiol* 275: L1219–L1227, 1998.
 183. **Van Heeckeren A, Walenga R, Konstan MW, Bonfield T, Davis PB, and Ferkol T.** Excessive inflammatory response of cystic fibrosis mice to bronchopulmonary infection with *Pseudomonas aeruginosa*. *J Clin Invest* 100: 2810–2815, 1997.
 184. **Varga K, Jurkuvenaite A, Wakefield J, Hong JS, Guimbellot JS, Venglarik CJ, Niraj A, Mazur M, Sorscher EJ, Collawn JF, and Bebek Z.** Efficient intracellular processing of the endogenous cystic fibrosis transmembrane conductance regulator in epithelial cell lines. *J Biol Chem* 279: 22578–22584, 2004.

185. **Velsor LW, van Heeckeren A, and Day BJ.** Antioxidant imbalance in the lungs of cystic fibrosis transmembrane conductance regulator protein mutant mice. *Am J Physiol Lung Cell Mol Physiol* 281: L31–L38, 2001.
186. **Venkatakrishnan A, Stecenko AA, King G, Blackwell TR, Brigham KL, Christman JW, and Blackwell TS.** Exaggerated activation of nuclear factor- κ B and altered I κ B- β processing in cystic fibrosis bronchial epithelial cells. *Am J Respir Cell Mol Biol* 23: 396–403, 2000.
187. **Verkman AS, Song Y, and Thiagarajah JR.** Role of airway surface liquid and submucosal glands in cystic fibrosis lung disease. *Am J Physiol Cell Physiol* 284: C2–C15, 2003.
188. **Wang GL, Jiang BH, Rue EA, and Semenza GL.** Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. *Proc Natl Acad Sci USA* 92: 5510–5514, 1995.
189. **Wang S, Yue H, Derin RB, Guggino WB, and Li M.** Accessory protein facilitated CFTR-CFTR interaction, a molecular mechanism to potentiate the chloride channel activity. *Cell* 103: 169–179, 2000.
190. **Weber AJ, Soong G, Bryan R, Saba S, and Prince A.** Activation of NF- κ B in airway epithelial cells is dependent on CFTR trafficking and Cl⁻ channel function. *Am J Physiol Lung Cell Mol Physiol* 281: L71–L78, 2001.
191. **Welsh MJ and Smith AE.** Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. *Cell* 73: 1251–1254, 1993.
192. **Willumsen NJ and Boucher RC.** Shunt resistance and ion permeabilities in normal and cystic fibrosis airway epithelia. *Am J Physiol Cell Physiol* 256: C1054–C1063, 1989.
193. **Willumsen NJ, Davis CW, and Boucher RC.** Intracellular Cl⁻ activity and cellular Cl⁻ pathways in cultured human airway epithelium. *Am J Physiol Cell Physiol* 256: C1033–C1044, 1989.
194. **Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, Birrer P, Bellon G, Berger J, Weiss T, Botzenhart K, Yankaskas JR, Randell S, Boucher RC, and Doring G.** Effects of reduced mucus oxygen concentration in airway *Pseudomonas* infections of cystic fibrosis patients. *J Clin Invest* 109: 317–325, 2002.
195. **Wu M, Grabe M, Adams S, Tsien RY, Moore HPH, and Machen TE.** Mechanisms of pH regulation in the regulated secretory pathway. *J Biol Chem* 276: 33027–33035, 2001.
196. **Wu Q, Lu Z, Verghese MW, and Randell SH.** Airway epithelial cell tolerance to *Pseudomonas aeruginosa*. *Respir Res* 6: 26, 2005.
197. **Xu Y, Clark JC, Aronow BJ, Dey CR, Liu C, Wooldridge JL, and Whitsett JA.** Transcriptional adaptation to cystic fibrosis transmembrane conductance regulator deficiency. *J Biol Chem* 278: 7674–7682, 2003.
198. **Xu Y, Liu C, Clark JC, and Whitsett JA.** Functional genomic responses to CFTR and CFTR Δ 508 in the lung. *J Biol Chem*. In Press.
199. **Zhang Z, Louboutin JP, Weiner DJ, Goldberg JB, and Wilson JM.** Human airway epithelial cells sense *Pseudomonas aeruginosa* infection via recognition of flagellin by Toll-like receptor 5. *Infect Immun* 73: 7151–7160, 2005.

